Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CACNA1G | O43497 | 6/20 | 0.48 |
| ▸ | CACNA1I | Q9P0X4 | 6/20 | 0.48 |
| ▸ | NPC1 | O15118 | 6/20 | 0.44 |
| ▸ | RAB9A | P51151 | 6/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.44 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.44 |
| ▸ | LMNA | P02545 | 5/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | CACNA1H | O95180 | 5/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.43 |
| ▸ | HDAC1 | Q13547 | 3/20 | 0.43 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.43 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.43 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.43 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.43 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.43 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.43 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.43 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.43 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16347294 | 0.84 | CACNA1G (0.50) | CACNA1GCACNA1INPC1SMN1; SMN2LMNA | |
| SCHEMBL5412525 | 0.84 | SMN1; SMN2 (0.47) | CACNA1GCACNA1INPC1RAB9ASMN1; SMN2 | |
| SCHEMBL28060209 | 0.83 | HDAC1 (0.45) | MAPTHDAC1HDAC3HDAC4HDAC7 | |
| SCHEMBL16347241 | 0.81 | HDAC1 (0.50) | SMN1; SMN2ALDH1A1HDAC1HDAC3HDAC4 | |
| SCHEMBL16388102 | 0.81 | ALDH1A1 (0.62) | CACNA1GCACNA1INPC1RAB9ASMN1; SMN2 | |
| SCHEMBL1196122 | 0.79 | CACNA1G (0.49) | CACNA1GCACNA1INPC1RAB9ACYP19A1 | |
| SCHEMBL13792153 | 0.77 | — | — | |
| SCHEMBL28862067 | 0.76 | HDAC1 (0.50) | CACNA1GCACNA1INPC1RAB9ASMN1; SMN2 | |
| SCHEMBL6969733 | 0.76 | CACNA1G (0.46) | CACNA1GCACNA1ICACNA1HALDH1A1CACNA1C | |
| SCHEMBL10247346 | 0.76 | GFER (0.60) | CACNA1GCACNA1INPC1RAB9ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 95 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260109699-A1 | AZOLE DERIVATIVES AS SHP2 INHIBITORS | IRBM S.P.A. (IT) | 2026-04-23 | — | — | US | disclosed |
| EP-3886904-B1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS INC (US) | 2026-04-22 | — | — | EP | disclosed |
| US-20260042749-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2026-02-12 | — | — | US | disclosed |
| US-12545659-B2 | IRAK degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2026-02-10 | — | — | US | disclosed |
| US-20250375526-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS INC (US) | 2025-12-11 | — | — | US | disclosed |
| US-20250325673-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS INC (US) | 2025-10-23 | — | — | US | disclosed |
| EP-4613773-A2 | IRAK DEGRADERS AND USES THEREOF | Kymera Therapeutics, Inc. (US) | 2025-09-10 | — | — | EP | disclosed |
| EP-4594324-A1 | AZOLE DERIVATIVES AS SHP2 INHIBITORS | IRBM S.P.A. (IT) | 2025-08-06 | — | — | EP | disclosed |
| EP-3731869-B1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS INC (US) | 2025-07-23 | — | — | EP | disclosed |
| US-20250195513-A1 | DEGRADATION OF IRAK4 BY CONJUGATION OF IRAK4 INHIBITORS WITH E3 LIGASE LIGAND AND METHODS OF USE | BEIGENE, LTD. (KY) | 2025-06-19 | — | — | US | disclosed |
| WO-2015002994-A2 | HETEROARYL COMPOUNDS USEFUL AS INHIBITORS OF SUMO ACTIVATING ENZYME | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2015-01-08 | — | — | WO | disclosed |
| WO-2015002994-A2 | HETEROARYL COMPOUNDS USEFUL AS INHIBITORS OF SUMO ACTIVATING ENZYME | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2015-01-08 | — | — | WO | disclosed |
| CN-103086971-A | Nitrogenous heterocyclic derivative, preparation method thereof and application thereof in preparation of histone deacetylase I inhibitor | GUANGZHOU INST BIOMED & HEALTH | 2013-05-08 | — | — | CN | disclosed |
| CN-1894235-A | N-(4-carbamimidoyl-benzyl) -2-alkoxy-2-heterocyclyl acetamides as inhibitors of the formation of coagulation factors xa, ixa and thrombin induced by factor viia | HOFFMANN LA ROCHE (CH) | 2007-01-10 | — | — | CN | disclosed |
| US-7056932-B2 | Heterocyclyl substituted 1-alkoxy acetic acid amides | HOFFMAN-LA ROCHE INC. (US) | 2006-06-06 | — | — | US | disclosed |
| US-20050137168-A1 | Heterocyclyl substituted 1-alkoxy acetic acid amides | HOFFMANN-LA ROCHE INC. | 2005-06-23 | — | — | US | disclosed |
| CN-1152873-C | Novel diphenyl-piperidine derivate | — | 2004-06-09 | — | — | CN | disclosed |
| US-6566376-B1 | For therapy of chemokine receptor related diseases and conditions such as rheumatoid arthritis, chronic obstructive pulmonary disease | ASTRAZENECA UK LIMITED (GB) | 2003-05-20 | — | — | US | disclosed |
| EP-1202984-B1 | DIPHENYL-PIPERIDINE DERIVATE | ASTRAZENECA UK LTD (GB) | 2003-03-05 | — | — | EP | disclosed |
| CN-1361775-A | Novel diphenyl-piperidine derivate | ASTRAZENECA UK LTD (GB) | 2002-07-31 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12545659-B2 | IRAK degraders and uses thereof | IRAK2, IRAK3, IRAK4 | CACNA1G 4774/4885CACNA1I 4796/4885NPC1 2384/4885 |
| US-20250325673-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | CACNA1G 4810/4885CACNA1I 4797/4885NPC1 3159/4885 |
| US-20050137168-A1 | Heterocyclyl substituted 1-alkoxy acetic acid amides | F12, TFPI, F11 | CACNA1G 1711/4885CACNA1I 1390/4885NPC1 4788/4885 |
| US-20260109699-A1 | AZOLE DERIVATIVES AS SHP2 INHIBITORS | PTPN1, PTPN5, PTPN3 | CACNA1G 1514/4885CACNA1I 1169/4885NPC1 1895/4885 |
| US-20250375526-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | CACNA1G 4810/4885CACNA1I 4797/4885NPC1 3159/4885 |
| US-20260042749-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK3, IRAK4 | CACNA1G 4746/4885CACNA1I 4761/4885NPC1 1765/4885 |
| US-20250195513-A1 | DEGRADATION OF IRAK4 BY CONJUGATION OF IRAK4 INHIBITORS WITH E3 LIGASE LIGAND AND METHODS OF USE | IRAK4, IRAK2, IRAK3 | CACNA1G 4835/4885CACNA1I 4816/4885NPC1 3056/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.